[Autoinflammatory diseases associated with RIPK1 mutations: A review of the literature].

Revue de la littérature sur les maladies auto-inflammatoires associées aux mutations du gène RIPK1.

Journal

La Revue de medecine interne
ISSN: 1768-3122
Titre abrégé: Rev Med Interne
Pays: France
ID NLM: 8101383

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 07 06 2022
accepted: 12 06 2022
pubmed: 6 7 2022
medline: 8 9 2022
entrez: 5 7 2022
Statut: ppublish

Résumé

Autoinflammatory diseases related to RIPK1 mutations have been recently described. Two distinct clinical phenotypes have been reported and depend on the type and location of the mutation. When the mutation is recessive with loss of function, patients develop a combined phenotype of immune deficiency with recurrent bacterial and fungal infections and signs of early inflammatory bowel disease, non-erosive polyarthritis and growth retardation. On the other hand, when the mutation is dominant, gain of function, the manifestations are only auto-inflammatory with extensive lymphoproliferation, oral lesions such as aphthosis or ulcers, abdominal pain and hepatosplenomegaly. The mutations described for the dominant form affect only the cleavage site of caspase 8 and the clinical phenotype is called CRIA for Cleavage-Resistant RIPK1-Induced Autoinflammatory syndrome. The recessive form is severe and life-threatening requiring hematopoietic stem cell transplantation while the dominant form responds well to interleukin-6 receptor antagonists. Thus, RIPK1 mutations can induce various clinical manifestations with two distinct phenotypes. Although still rare, because of their recent description, these diseases can be suspected by an internist, in front of recurrent digestive features and will be increasingly diagnosed in the future through the integration of this gene in the diagnostic chips dedicated to autoinflammatory diseases and early inflammatory bowel diseases, using next generation sequencing.

Identifiants

pubmed: 35786329
pii: S0248-8663(22)00542-2
doi: 10.1016/j.revmed.2022.06.005
pii:
doi:

Substances chimiques

RIPK1 protein, human EC 2.7.11.1
Receptor-Interacting Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

552-558

Informations de copyright

Copyright © 2022. Published by Elsevier Masson SAS.

Auteurs

A S Parentelli (AS)

Service des urgences pédiatriques, hôpital Robert-Debré, Assistance Publique des hôpitaux de Paris (AP-HP), 48, boulevard Sérurier, 75019 Paris, France; Institut Imagine, Inserm U1163, CNRS ERL 8254, université Paris Cité, Sorbonne Paris-Cité, Laboratoire d'excellence GR-Ex, Paris, France.

C Picard (C)

Centre d'études des déficits immunitaires (CEDI), département médico-universitaire BioPhyGen, hôpital Necker enfants malades, AP-HP, 149, rue de Sèvres, 75743 Paris Cedex 15, France; Université Paris Cité, Paris, France; Laboratoire d'Activation des Lymphocytes et Susceptibilité au virus EBV, Inserm UMR 1163, Institut Imagine, Paris, France; Centre de référence des déficits immunitaires héréditaires (CEREDIH), hôpital Necker-Enfants Malades, AP-HP, 149, rue de Sèvres, 75743 Paris Cedex 15, France.

G Boursier (G)

Laboratoire de génétique des maladies rares et auto-inflammatoires, service de génétique moléculaire et cytogénomique, CHU de Montpellier, Université de Montpellier, 371, avenue du Doyen Gaston-Giraud, 34295 Montpellier Cedex 5, France; Centre de référence des maladies Auto-Inflammatoires rares et de l'Amylose Inflammatoire (CEREMAIA), hôpital de Tenon, AP-HP, 75020 Paris, France.

I Melki (I)

Service de pédiatrie générale, maladies infectieuses et médecine interne pédiatrique, hôpital Robert-Debré, AP-HP, 48, boulevard Sérurier, 75019 Paris, France; Centre de référence des rhumatismes et auto-immunité systémique de l'enfant (RAISE), hôpital Necker Enfants Malades, AP-HP, 149, rue de Sèvres, 75743 Paris Cedex 15, France.

A Belot (A)

CIRI, Inserm U1111, service de néphrologie, rhumatologie, dermatologie pédiatrique, hôpital Femme-Mère-Enfant, hospices civils de Lyon, université de Lyon 1, 69677 Bron, France; Centre de référence des rhumatismes et auto-immunité systémique de l'enfant (RAISE), hôpital Necker Enfants Malades, AP-HP, 149, rue de Sèvres, 75743 Paris Cedex 15, France.

A Smahi (A)

Institut Imagine, Inserm U1163, CNRS ERL 8254, université Paris Cité, Sorbonne Paris-Cité, Laboratoire d'excellence GR-Ex, Paris, France.

S Georgin-Lavialle (S)

Département de médecine interne, DHUI2B, département hospitalo-universitaire inflammation, immunopathologie, biothérapie, hôpital Tenon, université Paris 6, Pierre et Marie Curie, AP-HP, 4, rue de la Chine, 75020 Paris, France; Centre de référence des maladies Auto-Inflammatoires rares et de l'Amylose Inflammatoire (CEREMAIA), hôpital de Tenon, AP-HP, 75020 Paris, France. Electronic address: sophie.georgin-lavialle@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH